Trexquant Investment LP Has $4.31 Million Stock Holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Trexquant Investment LP lessened its position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 30.2% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 206,489 shares of the biopharmaceutical company's stock after selling 89,171 shares during the period. Trexquant Investment LP owned approximately 0.17% of Catalyst Pharmaceuticals worth $4,309,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Steward Partners Investment Advisory LLC acquired a new stake in Catalyst Pharmaceuticals during the 4th quarter worth $27,000. Farther Finance Advisors LLC raised its position in shares of Catalyst Pharmaceuticals by 125.1% during the fourth quarter. Farther Finance Advisors LLC now owns 2,690 shares of the biopharmaceutical company's stock worth $56,000 after purchasing an additional 1,495 shares during the period. Wilmington Savings Fund Society FSB bought a new position in shares of Catalyst Pharmaceuticals during the 4th quarter valued at about $65,000. KBC Group NV increased its stake in Catalyst Pharmaceuticals by 48.8% during the 4th quarter. KBC Group NV now owns 4,699 shares of the biopharmaceutical company's stock worth $98,000 after purchasing an additional 1,542 shares in the last quarter. Finally, Thurston Springer Miller Herd & Titak Inc. acquired a new stake in Catalyst Pharmaceuticals during the 4th quarter worth approximately $134,000. 79.22% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Catalyst Pharmaceuticals news, insider Brian Elsbernd sold 62,975 shares of Catalyst Pharmaceuticals stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $22.98, for a total value of $1,447,165.50. Following the completion of the transaction, the insider now directly owns 188,564 shares of the company's stock, valued at $4,333,200.72. The trade was a 25.04 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Gary Ingenito sold 44,904 shares of the stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $22.09, for a total value of $991,929.36. Following the sale, the insider now directly owns 68,873 shares in the company, valued at approximately $1,521,404.57. This trade represents a 39.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 11.00% of the company's stock.

Remove Ads

Catalyst Pharmaceuticals Stock Down 7.7 %

Shares of CPRX traded down $1.74 during midday trading on Thursday, reaching $21.00. 405,804 shares of the stock were exchanged, compared to its average volume of 1,136,192. The stock's 50 day simple moving average is $22.68 and its 200 day simple moving average is $21.98. The company has a market cap of $2.55 billion, a P/E ratio of 17.85, a PEG ratio of 3.31 and a beta of 0.79. Catalyst Pharmaceuticals, Inc. has a twelve month low of $14.47 and a twelve month high of $26.16.

Analyst Ratings Changes

CPRX has been the subject of several research analyst reports. Baird R W upgraded shares of Catalyst Pharmaceuticals to a "strong-buy" rating in a report on Monday, February 3rd. StockNews.com upgraded Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Friday, February 28th. HC Wainwright restated a "buy" rating and issued a $35.00 price target on shares of Catalyst Pharmaceuticals in a report on Friday, February 28th. Bank of America reiterated a "buy" rating and set a $30.00 price objective on shares of Catalyst Pharmaceuticals in a report on Thursday, January 9th. Finally, Robert W. Baird boosted their target price on Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the company an "outperform" rating in a research note on Monday, March 3rd. Seven equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus target price of $32.29.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.